Michael Morneau - Viking Therapeutics Vice Administration
| VKTX Stock | USD 64.67 1.80 2.71% |
Executive
Mr. Michael Morneau is Vice President Finance and Administration of the Company effective April 6, 2018. Mr. Morneau has over 20 years of accounting and financial experience at public and private companies in the biotechnology and accounting industries. Prior to Viking, from 2009 to 2014, he was VP of Finance and Chief Accounting Officer at Trius Therapeutics, Inc., a subsidiary of Cubist Pharmaceuticals, Inc., a pharmaceutical company, following Cubists acquisition of Trius in September 2013. Prior to Trius, from 2008 to 2009, he was Director of Lilly Research Labs Finance at Eli Lilly and Company, a pharmaceutical company. Prior to Eli Lilly, from 2006 to 2008, he was Director of Finance and Accounting at SGX Pharmaceuticals, Inc., a biotechnology company, which was acquired by Eli Lilly. Prior to SGX, from 2004 to 2006, he was Controller at Momenta Pharmaceuticals, Inc., a biotechnology company since 2018.
| Age | 59 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121 |
| Phone | 858 704 4660 |
| Web | https://www.vikingtherapeutics.com |
Viking Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2347) % which means that it has lost $0.2347 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3479) %, meaning that it created substantial loss on money invested by shareholders. Viking Therapeutics' management efficiency ratios could be used to measure how well Viking Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.3 in 2024. At this time, Viking Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 385.6 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 755.8 K in 2024.Similar Executives
| Found 12 records | EXECUTIVE Age | ||
| Renate Gloggner | Molecular Partners AG | 54 | |
| Crystal Zuckerman | Pmv PharmaceuticalsInc | N/A | |
| Tim Smith | Pmv PharmaceuticalsInc | N/A | |
| Marc MD | Pmv PharmaceuticalsInc | N/A | |
| MD MBA | Molecular Partners AG | N/A | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Binh Vu | Pmv PharmaceuticalsInc | N/A | |
| Michael Carulli | Pmv PharmaceuticalsInc | N/A | |
| Anne DVM | Molecular Partners AG | N/A | |
| Robert Ticktin | Pmv PharmaceuticalsInc | 62 | |
| Daniel Steiner | Molecular Partners AG | N/A | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.23 |
Viking Therapeutics Leadership Team
Elected by the shareholders, the Viking Therapeutics' board of directors comprises two types of representatives: Viking Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viking. The board's role is to monitor Viking Therapeutics' management team and ensure that shareholders' interests are well served. Viking Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viking Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Rowland, Director | ||
| Kathy Rouan, Director | ||
| Matthew Singleton, Independent Director | ||
| Stephanie Diaz, IR Contact Officer | ||
| Marianne Mancini, Chief Officer | ||
| Greg Zante, Vice President Finance & Operartions | ||
| Stephen Webster, Independent Director | ||
| Rochelle Hanley, Chief Medical Officer | ||
| Catherine Kelleher, Vice President - Clinical Development | ||
| Lawson Macartney, Independent Director | ||
| Michael Morneau, Vice Administration | ||
| Amy Broidrick, Senior Vice President - Corporate Development | ||
| Hiroko Masamune, Chief Development Officer | ||
| Geoffrey Barker, Senior Development | ||
| Brian Lian, CEO and President and Director | ||
| Gregory Zante, Vice President - Finance and Operations | ||
| Matthew Foehr, Director |
Viking Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Viking Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 6.32 B | ||||
| Shares Outstanding | 110.22 M | ||||
| Shares Owned By Insiders | 6.03 % | ||||
| Shares Owned By Institutions | 72.03 % | ||||
| Number Of Shares Shorted | 9.52 M | ||||
| Price To Earning | (3.17) X | ||||
| Price To Book | 21.71 X | ||||
| EBITDA | (100.83 M) |
Viking Therapeutics Investors Sentiment
The influence of Viking Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Viking. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Viking Therapeutics' public news can be used to forecast risks associated with an investment in Viking. The trend in average sentiment can be used to explain how an investor holding Viking can time the market purely based on public headlines and social activities around Viking Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Viking Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Viking Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Viking Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Viking Therapeutics.
Viking Therapeutics Implied Volatility | 163.56 |
Viking Therapeutics' implied volatility exposes the market's sentiment of Viking Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Viking Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Viking Therapeutics stock will not fluctuate a lot when Viking Therapeutics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Viking Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Viking Therapeutics' short interest history, or implied volatility extrapolated from Viking Therapeutics options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Viking Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Viking Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Viking Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Viking Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viking Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Viking Stock analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Viking Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viking Therapeutics. If investors know Viking will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viking Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Return On Assets (0.23) | Return On Equity (0.35) |
The market value of Viking Therapeutics is measured differently than its book value, which is the value of Viking that is recorded on the company's balance sheet. Investors also form their own opinion of Viking Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viking Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viking Therapeutics' market value can be influenced by many factors that don't directly affect Viking Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viking Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viking Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viking Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.